Logo image of AMPH

AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis

NASDAQ:AMPH - Nasdaq - US03209R1032 - Common Stock - Currency: USD

23.2  -0.38 (-1.61%)

After market: 23.2 0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to AMPH. AMPH was compared to 195 industry peers in the Pharmaceuticals industry. While AMPH belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMPH may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make AMPH suitable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

AMPH had positive earnings in the past year.
In the past year AMPH had a positive cash flow from operations.
In the past 5 years AMPH has always been profitable.
Each year in the past 5 years AMPH had a positive operating cash flow.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

With an excellent Return On Assets value of 8.71%, AMPH belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
AMPH's Return On Equity of 18.85% is amongst the best of the industry. AMPH outperforms 91.79% of its industry peers.
AMPH's Return On Invested Capital of 11.31% is amongst the best of the industry. AMPH outperforms 89.74% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is in line with the industry average of 14.87%.
Industry RankSector Rank
ROA 8.71%
ROE 18.85%
ROIC 11.31%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

AMPH has a Profit Margin of 19.38%. This is amongst the best in the industry. AMPH outperforms 92.82% of its industry peers.
AMPH's Profit Margin has improved in the last couple of years.
The Operating Margin of AMPH (26.65%) is better than 92.31% of its industry peers.
In the last couple of years the Operating Margin of AMPH has grown nicely.
AMPH has a better Gross Margin (50.50%) than 64.10% of its industry peers.
In the last couple of years the Gross Margin of AMPH has grown nicely.
Industry RankSector Rank
OM 26.65%
PM (TTM) 19.38%
GM 50.5%
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
AMPH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMPH has more shares outstanding
Compared to 1 year ago, AMPH has an improved debt to assets ratio.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

AMPH has an Altman-Z score of 2.39. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of AMPH (2.39) is better than 70.26% of its industry peers.
AMPH has a debt to FCF ratio of 4.02. This is a neutral value as AMPH would need 4.02 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 4.02, AMPH belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.
AMPH has a Debt/Equity ratio of 0.80. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
AMPH has a worse Debt to Equity ratio (0.80) than 68.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.02
Altman-Z 2.39
ROIC/WACC1.22
WACC9.25%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.95 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Current ratio (2.95) which is comparable to the rest of the industry.
AMPH has a Quick Ratio of 2.02. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AMPH (2.02) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.02
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

AMPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.30%.
Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 61.62% on average per year.
The Revenue has grown by 8.05% in the past year. This is quite good.
Measured over the past years, AMPH shows a quite strong growth in Revenue. The Revenue has been growing by 17.82% on average per year.
EPS 1Y (TTM)-4.3%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-28.85%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-0.76%

3.2 Future

AMPH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.72% yearly.
Based on estimates for the next years, AMPH will show a small growth in Revenue. The Revenue will grow by 4.44% on average per year.
EPS Next Y-16.92%
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
EPS Next 5Y-0.72%
Revenue Next Year-1.48%
Revenue Next 2Y1.8%
Revenue Next 3Y2.18%
Revenue Next 5Y4.44%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 6.52, the valuation of AMPH can be described as very cheap.
AMPH's Price/Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 94.87% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.45. AMPH is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 6.37, the valuation of AMPH can be described as very cheap.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 93.85% of the companies are valued more expensively.
AMPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.90, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 6.52
Fwd PE 6.37
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 94.87% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaply inside the industry as 94.36% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.28
EV/EBITDA 5.56
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.11
EPS Next 2Y-2.84%
EPS Next 3Y0.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (7/3/2025, 8:27:34 PM)

After market: 23.2 0 (0%)

23.2

-0.38 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners72.67%
Inst Owner Change-5.17%
Ins Owners8.72%
Ins Owner Change6.64%
Market Cap1.09B
Analysts76.67
Price Target33.66 (45.09%)
Short Float %11.27%
Short Ratio7.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.55%
Min EPS beat(2)-4.55%
Max EPS beat(2)5.65%
EPS beat(4)2
Avg EPS beat(4)3.88%
Min EPS beat(4)-4.74%
Max EPS beat(4)19.17%
EPS beat(8)5
Avg EPS beat(8)11.41%
EPS beat(12)8
Avg EPS beat(12)16.64%
EPS beat(16)11
Avg EPS beat(16)20.36%
Revenue beat(2)0
Avg Revenue beat(2)-2.65%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.43%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-0.34%
Revenue beat(12)6
Avg Revenue beat(12)-0.04%
Revenue beat(16)9
Avg Revenue beat(16)0.9%
PT rev (1m)-6.38%
PT rev (3m)-14.29%
EPS NQ rev (1m)1.36%
EPS NQ rev (3m)4.86%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)0.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.43%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-1.89%
Valuation
Industry RankSector Rank
PE 6.52
Fwd PE 6.37
P/S 1.5
P/FCF 7.28
P/OCF 5.66
P/B 1.46
P/tB 6.56
EV/EBITDA 5.56
EPS(TTM)3.56
EY15.34%
EPS(NY)3.64
Fwd EY15.71%
FCF(TTM)3.19
FCFY13.74%
OCF(TTM)4.1
OCFY17.66%
SpS15.5
BVpS15.94
TBVpS3.54
PEG (NY)N/A
PEG (5Y)0.11
Profitability
Industry RankSector Rank
ROA 8.71%
ROE 18.85%
ROCE 13.64%
ROIC 11.31%
ROICexc 13.56%
ROICexgc 26.64%
OM 26.65%
PM (TTM) 19.38%
GM 50.5%
FCFM 20.56%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexcg growth 3Y24.9%
ROICexcg growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.02
Debt/EBITDA 2.39
Cap/Depr 73.47%
Cap/Sales 5.88%
Interest Coverage 7.56
Cash Conversion 76.31%
Profit Quality 106.07%
Current Ratio 2.95
Quick Ratio 2.02
Altman-Z 2.39
F-Score7
WACC9.25%
ROIC/WACC1.22
Cap/Depr(3y)86.1%
Cap/Depr(5y)106.5%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-4.3%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-28.85%
EPS Next Y-16.92%
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
EPS Next 5Y-0.72%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-0.76%
Revenue Next Year-1.48%
Revenue Next 2Y1.8%
Revenue Next 3Y2.18%
Revenue Next 5Y4.44%
EBIT growth 1Y-7.98%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-5.73%
EBIT Next 3Y3.45%
EBIT Next 5Y5.95%
FCF growth 1Y192.27%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y145.14%
OCF growth 3Y29.62%
OCF growth 5Y38.57%